Sugi Predict

Sugi Predict / Compounds / SCHEMBL2214341

SCHEMBL2214341

SCHEMBL2214341

O=C1Nc2ccccc2CCC1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.52
▸ MAPK13 O15264 1/20 0.52
▸ MAPK12 P53778 1/20 0.52
▸ MAPK11 Q15759 1/20 0.52
▸ MAPK14 Q16539 1/20 0.52
▸ MAPT P10636 1/20 0.49
▸ AHR P35869 1/20 0.44
▸ PDK2 Q15119 1/20 0.44
▸ PYGL P06737 5/20 0.44
▸ PYGM P11217 5/20 0.44
▸ BRD4 O60885 2/20 0.41
▸ CREBBP Q92793 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ RIPK1 Q13546 3/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7350629 0.90 MAPT (0.54) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL7438513 0.88 MAPT (0.53) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL29035761 0.83 PYGL (0.39) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL4700977 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL12598688 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL1270022 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL13904707 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL859143 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL22048708 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL2608569 0.79 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113149907-A Synthetic method of 3-bromo-1, 3,4, 5-tetrahydro-2H-1-benzazepin-2-one 河南普美济华医药科技有限公司 2021-07-23 — — CN claimed
CN-119487004-A Improved process for the synthesis of benazepril intermediates 阿缇制药有限公司 2025-02-18 — — CN disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 — — US disclosed
WO-2023181054-A1 IMPROVED PROCESS FOR SYNTHESIS OF BENAZEPRIL INTERMEDIATE AARTI INDUSTRIES LIMITED (IN) 2023-09-28 — — WO disclosed
EP-4225447-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
CN-110835319-B Synthesis method of benazepril intermediate and benazepril hydrochloride 杭州馨佳源环保科技有限公司 2023-06-20 — — CN disclosed
CN-110835319-B Synthesis method of benazepril intermediate and benazepril hydrochloride 杭州馨佳源环保科技有限公司 2023-06-20 — — CN disclosed
CN-113292495-B Synthesis method of (S) -amino compound 迪嘉药业集团有限公司 2022-09-13 — — CN disclosed
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND NAGASE & CO., LTD. (JP) 2022-05-12 — — US disclosed
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
US-5677297-A ENZYME INHIBITOR FOR TREATING THE HEART FAILURE TO REDUCE THE CARDIAC PRESSURE, DIURETICS SOLVAY PHARMACEUTICALS GMBH (DE) 1997-10-14 — — US disclosed
EP-0733642-A1 Benzazepin-, benzoxazepin- and benzothiazepin-N-acetic acid-derivatives, their preparation and their pharmaceutical compositions Kali-Chemie Pharma GmbH (DE) 1996-09-25 — — EP disclosed
US-4757068-A Lactams and bicyclic lactams useful as cholecystokinin antagonists MERCK & CO., INC. (US) 1988-07-12 — — US disclosed
US-4692522-A Benzofused lactams useful as cholecystokinin antagonists MERCK & CO., INC. (US) 1987-09-08 — — US disclosed
WO-1986007057-A1 METHYL DERIVATIVES OF METHYLATED BIS 7H PYRIDOCARBAZOLES AND FARMACEUTICAL COMPOSITIONS CONTAINING THEM CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1986-12-04 — — WO disclosed
US-4600534-A Process and intermediates for manufacture of 3-(5-amino-1-carboxypentylamino)-tetrahydro-1-benzazepin-2-one-1-acetic acid CIBA-GEIGY CORPORATION (US) 1986-07-15 — — US disclosed
US-4575503-A ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1986-03-11 — — US disclosed
US-4473575-A ANGIOTENSIN INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1984-09-25 — — US disclosed
US-4410520-A ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1983-10-18 — — US disclosed
EP-0072352-A1 Benzazepin-2-ones, process for their preparation, pharmaceutical preparations containing these compounds and the compounds for therapeutical use CIBA-GEIGY AG (CH) 1983-02-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B NPC1 165/4885MAPK13 3632/4885MAPK12 2917/4885
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND VIP, IAPP, RPS27A NPC1 3099/4885MAPK13 733/4885MAPK12 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.